AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government’s strategy.
As reported by Reuters this week, Prime Minister Theresa May’s office has asked companies listed in the blue-chip FTSE 100 index to put their name to a public letter welcoming the government’s efforts to make Brexit a success.
“The reason I didn’t sign is that I felt there are so many areas that are still uncertain. How can we support something that we don’t really understand fully?” Soriot told Reuters on the sidelines of a cancer conference in Madrid.
Executives at several companies have said privately that the request went down badly with many large corporations but they have been reluctant to comment publicly.
Soriot said his refusal to sign did not mean the drugmaker disagreed with Britain’s decision to leave the European Union, adding that it could have some positive aspects if it went hand-in-hand with increased support for the UK life sciences sector.
But the deep uncertainty about future terms of trade just 18 months before Brexit happens in March 2019 means exports of medicines could be hampered, he said.
“What is starting to worry me, I must say, is the potential for the one thing I didn’t think would happen which is a hard Brexit,” he said.
“If there is no extension we will be left in limbo because the UK will come out of Europe and we will have no trade agreements.”
Britain’s second-biggest pharmaceuticals company makes a large amount of products in the north of England, including the cancer drug Zoladex, sales of which are increasing rapidly in China and other countries around the world.
“We need to know that is not going to be disrupted because right now we are exporting under a trade agreement between the EU and China,” Soriot said.
Many companies fear that Britain’s move to leave the world’s largest trading bloc will increase bureaucracy, drive up costs and eat into profitability.
The public letter, which May’s advisers wanted Soriot and other business leaders to sign, states that signatories are confident that “global Britain has the potential to become one of the most productive economies of the 21st century”.
By Ben Hirschler
Source: Reuters
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
